Aktuellt
SENASTE
Redeye updates its estimates following Surgical Science’s Q3 2024 report, which beat our expectations. Educational Products continued its sequential recovery, while solid Industry/OEM sales matched our projections. We expect a seasonally strong fourth quarter and solid growth in 2025e. We nudge up our estimates and valuation.
LÄS MER
